Jorge Alamo, MD
Family Medicine · Odessa, TXNPI 1063859189
Payments from drug & device makers
Across 169 payments — averaging $619.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kedplasma LLC$101K
- Lilly USA, LLC$1K
- AstraZeneca$639
- Novo Nordisk$623
- AbbVie$157
- Boehringer Ingelheim$133
- plus $1K from 23 others
What the payments were for
- Consulting fees$101,00096%
- Food & beverage$3,6804%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kedplasma LLC | 26 | $101,000 |
| Lilly USA, LLC | 55 | $1,027 |
| AstraZeneca | 24 | $639 |
| Novo Nordisk | 22 | $623 |
| AbbVie(2 entities) | 3 | $157 |
| Boehringer Ingelheim | 2 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $112 |
| Sanofi | 2 | $111 |
| Smith+Nephew | 1 | $100 |
| Shire North American Group Inc | 1 | $89 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $80 |
| Surgalign Spine Technologies, Inc. | 1 | $80 |
| Acadia Pharmaceuticals Inc | 1 | $77 |
| Abbott | 3 | $65 |
| Veran Medical Technologies, Inc. | 1 | $58 |
| Avanir Pharmaceuticals, Inc. | 1 | $45 |
| Pacira Therapeutics, Inc. | 3 | $39 |
| Amgen | 2 | $34 |
| Genentech USA, Inc. | 2 | $33 |
| Johnson & Johnson | 2 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Pfizer | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| GSK | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$246
- JARDIANCE$120
- BREZTRI$100
- COLLAGENASE SANTYL$100
How this compares
$104,680 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 79 | $96,909 |
| JardianceEmpagliflozin | 63 | $79,854 |
| OzempicSemaglutide | 83 | $79,461 |
| EliquisApixaban | 62 | $44,626 |
| TrulicityDulaglutide | 27 | $29,619 |
| FarxigaDapagliflozin Propanediol | 17 | $23,884 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $22,819 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $16,054 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $15,877 |
| JentaduetoLinagliptin/Metformin Hcl | 15 | $10,534 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $7,778 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $7,542 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $4,961 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $4,949 |
| Atorvastatin Calcium | 403 | $3,223 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,027 | $126,529106 claims |
| Boehringer IngelheimJardiance, Jentadueto | $133 | $90,38878 claims |
| Novo NordiskOzempic | $623 | $79,46183 claims |
| PfizerEliquis | $16 | $44,62662 claims |
| MerckJanumet Xr, Janumet | $18 | $31,93129 claims |
| AstraZenecaFarxiga, Symbicort | $639 | $28,84435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Odessa
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.